CYP19A1 and Obesity: Obesity also has implications in the adjuvant therapeutic setting: patients with large breasts may receive increased doses of radiation, chemotherapy may have increased toxicity and failure rates in the context of obesity irrespective of tumor size, nodal status, and hormone receptor status, whereas aromatase inhibitors may be less effective in overweight and obese populations 56.